pharmaceutical investing Ironwood and Alnylam Enter US GI Disease Education and Promotional Agreement
pharmaceutical investing Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
Arbutus’ LNP Licensee Alnylam Announces FDA Approval of ONPATTRO (patisiran), for the Treatment of ATTR Amyloidosis
